Another Alzheimer's Setback As Roche And Lilly Drugs Fail
Fresh Disappointment For Amyloid Hypothesis
As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.
